Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rovalpituzumab Tesirine

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Four Independent Studies Show Rovalpituzumab Tesirine Ineffective Against SCLC
    Four Independent Studies Show Rovalpituzumab Tesirine Ineffective Against SCLC

    07 Sep 2021

    // SCIENCEDAILY

    https://www.sciencedaily.com/releases/2021/09/210907110650.htm#:~:text=Four%20independent%20studies%20published%20in,first%20study%20on%20the%20therapy

    SCIENCEDAILY
    07 Sep 2021
    Share Share
    AbbVie shuts Rova-T development in first-line advanced small-cell lung cancer
    AbbVie shuts Rova-T development in first-line advanced small-cell lung cancer

    31 Aug 2019

    // Matt Fellows PHARMAFILE

    http://www.pharmafile.com/news/527670/abbvie-shuts-down-rova-t-development-first-line-advanced-small-cell-lung-cancer-followin

    Matt Fellows PHARMAFILE
    31 Aug 2019
    Share Share
    AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure
    AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

    29 Mar 2019

    // Alex Keown BIOSPACE

    https://www.biospace.com/article/abbvie-cuts-178-stemcentrx-employees-months-after-rova-t-failure/

    Alex Keown BIOSPACE
    29 Mar 2019
    Share Share
    Abbvie to record $4 billion impairment charges on Stemcentrx assets
    Abbvie to record $4 billion impairment charges on Stemcentrx assets

    05 Jan 2019

    // Jonathan Sl REUTERS

    https://www.reuters.com/article/us-abbvie-stemcentrx-write-down/abbvie-to-record-4-billion-impairment-charges-on-stemcentrx-assets-idUSKCN1OY212

    Jonathan Sl REUTERS
    05 Jan 2019
    Share Share
    Mega-blockbuster valuation AbbVie assigned to Rova-T starting to vanish, quietly
    Mega-blockbuster valuation AbbVie assigned to Rova-T starting to vanish, quietly

    04 Jan 2019

    // John Carroll ENDPTS

    https://endpts.com/remember-that-mega-blockbuster-valuation-abbvie-assigned-to-rova-t-its-starting-to-vanish-quietly/

    John Carroll ENDPTS
    04 Jan 2019
    Share Share
    AbbVie dishes out $105M for CD39 pact with Tizona’s new CEO from Roche
    AbbVie dishes out $105M for CD39 pact with Tizona’s new CEO from Roche

    03 Jan 2019

    // Amber Tong ENDPTS

    https://endpts.com/after-blueprinting-rd-hub-abbvie-dishes-out-105m-for-cd39-pact-with-tizonas-new-ceo-from-roche/

    Amber Tong ENDPTS
    03 Jan 2019
    Share Share